- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02155504
A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects
2014년 10월 29일 업데이트: Astellas Pharma Europe B.V.
A Phase 1, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects, Including a Drug-drug Interaction Part With Itraconazole
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single ascending oral doses of ASP3700 in healthy male subjects.
This study will also explore the effect of itraconazole (another drug) on the PK of ASP3700, as well as to evaluate the safety and tolerability of ASP3700 alone and in combination with itraconazole in healthy male subjects.
연구 개요
상세 설명
This study consists of 2 parts: Part 1 is a single ascending dose study where subjects will receive either ASP3700 or matching placebo; Part 2 is a drug-drug interaction (DDI) open-label, crossover study comprised of 1 sequence with 2 investigational periods where subjects will receive ASP3700 alone and in combination with itraconazole.
연구 유형
중재적
등록 (실제)
44
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Harrow, 영국, HA1 3UJ
- PAREXEL Early Phase Clinical Unit
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
남성
설명
Inclusion Criteria:
- Subject has a body mass index range of 18.5 - 30.0 kg/m2. The subject weighs at least 50 kg.
- Subject and his female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.
- Subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration.
Exclusion Criteria:
- Subject has a known or suspected hypersensitivity to ASP3700 (parts 1 and 2) or itraconazole (part 2 only) or significant adverse reactions to historical cannabinoid use or any components of the formulations used.
- Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase, gamma-glutamyl transaminase, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case the assessment may be repeated once (upon admission to the clinical unit).
- Subject has a history of a suicide attempt or suicidal behavior. Any recent suicidal ideation within the last 3 months or who are at significant risk to commit suicide, as judged by the Investigator using the C-SSRS (a level of 4 or 5) at screening or upon admission to the clinical unit.
- Subject has any clinically significant abnormality following the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests at screening or upon admission to the clinical unit.
- Subject has a pulse rate < 40 or > 90 beats per minute; mean SBP > 140 mmHg; mean DBP > 90 mmHg (vital signs measurements taken in triplicate after subject has been resting in supine position for 5 minutes; pulse rate will be measured automatically) upon admission to the clinical unit.
- Subject has a mean corrected QT interval using Fridericia's formula (QTcF) interval > 430 ms at day -1. If the mean QTcF exceeds the limits above, 1 additional triplicate ECG can be taken.
- Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
- Subject has a history of drinking more than 21 units of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.
- Subject has consumed grapefruit, grapefruit-containing products or Seville orange-containing products within 72 hours prior to admission to the clinical unit.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ASP3700 single ascending dose cohort
Part 1
|
oral
|
|
위약 비교기: Placebo single ascending dose cohort
Part 1
|
경구
|
|
실험적: ASP3700 alone
Part 2
|
oral
|
|
활성 비교기: ASP3700 and itraconazole
Part 2
|
oral
경구
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety as assessed by adverse events (Part 1)
기간: up to end of study visit (up to 16 days)
|
up to end of study visit (up to 16 days)
|
|
|
Safety as assessed by vital signs (Part 1)
기간: up to end of study visit (up to 16 days)
|
up to end of study visit (up to 16 days)
|
|
|
Safety as assessed by laboratory tests (Part 1)
기간: up to end of study visit (up to 16 days)
|
Laboratory tests includes the measurement of sex-hormone related biomarkers and exploratory renal biomarkers.
|
up to end of study visit (up to 16 days)
|
|
Safety as assessed by electrocardiogram (ECG) measurements (Part 1)
기간: up to end of study visit (up to 16 days)
|
ECG measurements include routine 12-lead ECG, continuous cardiac monitoring (Holter ECG) and real-time cardiac monitoring (ECG telemetry)
|
up to end of study visit (up to 16 days)
|
|
Safety as assessed by Bond and Lader VAS (Part 1)
기간: Up to Day 2
|
visual analogue scale (VAS)
|
Up to Day 2
|
|
Safety as assessed by C-SSRS (Part 1)
기간: Up to end of study visit (up to 16 days)
|
Columbia - Suicide Severity Rating Scale (C-SSRS)
|
Up to end of study visit (up to 16 days)
|
|
Safety as assessed by ARCI-49 (Part 1)
기간: Up to Day 2
|
Addiction Research Center Inventory (ARCI)-49 (49-item)
|
Up to Day 2
|
|
Pharmacokinetic parameter of itraconazole (plasma): Ctrough (Part 2)
기간: Days 3-13
|
Concentration immediately prior to dosing at multiple dosing
|
Days 3-13
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Area under the concentration-time curve from time of dosing extrapolated to time infinity (AUCinf)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUCinf (%extrap) (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Percentage of AUCinf due to extrapolation from tlast to time infinity (AUCinf [%extrap])
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): AUClast (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Area under the concentration-time curve from the time of dosing to the last measurable concentration (AUClast)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Cmax (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Maximum concentration (Cmax)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma):λz (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Terminal elimination rate constant (λz)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): MRT (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Mean residence time (MRT)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tlag (Part 2)
기간: Day 1 (period 1 and 2)
|
Time prior to the time corresponding to the first measurable (nonzero) concentration (tlag)
|
Day 1 (period 1 and 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): tmax (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Time of maximum concentration (tmax)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): t1/2 (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Terminal elimination half-life (t1/2)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (plasma): Vz/F (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Apparent volume of distribution during the terminal elimination phase after extravascular dosing (Vz/F)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Cumulative amount of study drug excreted into urine from time of dosing up to the collection time of the last measurable concentration (Aelast)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Cumulative amount of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aelast% (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Percentage of study drug excreted into urine from the time of dosing up to the collection time of the last measurable concentration (Aelast%)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): Aeinf% (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Percentage of study drug excreted into urine from time of dosing extrapolated to time infinity (Aeinf%)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Pharmacokinetic parameter of ASP3700 with and without itraconazole (urine): CLR (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2)
|
Renal clearance (CLR)
|
Days 1-7 (period 1) and Days 1-13 (period 2)
|
|
Safety as assessed by orthostatic evaluation (or blood pressure change in orthostatic challenge test) (Part 1)
기간: Up to Day 7
|
Up to Day 7
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Composite of pharmacokinetics of ASP3700: AUCinf, AUCinf(%extrap), AUClast, Cmax, CL/F, λz, MRT, tlag, tmax, t½, Vz/F (plasma) (Part 1)
기간: up to Day 7
|
up to Day 7
|
|
Title: Composite of pharmacokinetics of ASP3700: Aelast, Aeinf, Aelast%, Aeinf%, CLR (urine) (Part 1)
기간: up to Day 7
|
up to Day 7
|
|
Safety as assessed by adverse events, vital signs, orthostatic evaluation, laboratory tests, ECG measurements, C-SSRS, Bond & Lader VAS, ARCI-49 (Part 2)
기간: Days 1-7 (period 1) and Days 1-13 (period 2) and at end of study visit (up to 22 days)
|
Days 1-7 (period 1) and Days 1-13 (period 2) and at end of study visit (up to 22 days)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2014년 5월 1일
기본 완료 (실제)
2014년 10월 1일
연구 완료 (실제)
2014년 10월 1일
연구 등록 날짜
최초 제출
2014년 5월 28일
QC 기준을 충족하는 최초 제출
2014년 6월 2일
처음 게시됨 (추정)
2014년 6월 4일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 10월 30일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 10월 29일
마지막으로 확인됨
2014년 10월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 3700-CL-0001
- 2013-005018-36 (EudraCT 번호)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
위약에 대한 임상 시험
-
Newish Biotech (Wuxi) Co., Ltd.아직 모집하지 않음
-
Chiesi Farmaceutici S.p.A.아직 모집하지 않음
-
Nature's Sunshine Products, Inc.아직 모집하지 않음
-
Yale UniversityHartford HealthCare아직 모집하지 않음
-
Acesion Pharma모병심방세동(AF)헝가리, 폴란드, 불가리아, 덴마크, 독일, 네덜란드, 이탈리아, 세르비아
-
Shanghai Lanyi Therapeutics Co., Ltd.완전한
-
University of Texas Southwestern Medical Center아직 모집하지 않음
-
Universidad Autonoma de Zacatecas모집하지 않고 적극적으로